Navigation Links
MAP Pharmaceuticals Announces Resignation of Chief Medical Officer
Date:2/5/2008

MOUNTAIN VIEW, Calif., Feb. 5 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company, announced today that Stephen B. Shrewsbury, M.B., Ch.B., Chief Medical Officer, will be leaving the company for personal reasons in early March 2008. Dr. Shrewsbury plans to provide consulting services to the company for a period of time after his departure.

"We want to thank Steve for his many contributions and wish him the best in his future endeavors," said Timothy S. Nelson, President and Chief Executive Officer. "Steve has put into place a strong leadership team in the clinical organization to advance our two lead programs for pediatric asthma and migraine through late-stage development."

"I am happy to have played a role in the development of our two lead product candidates, Unit Dose Budesonide (UDB) and MAP0004," stated Stephen B. Shrewsbury, M.B., Ch.B., Chief Medical Officer. "I made the difficult decision to leave MAP Pharmaceuticals for personal reasons and believe that the company is well positioned to move forward with these very promising programs."

About MAP Pharmaceuticals

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from diseases that the company believes are not treated adequately by currently available medicines. The company uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The company has several product candidates in clinical development that address large market opportunities, including its two most advanced product candidates
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... According to an article in the June ... nearly 30 million Americans tan indoors each year and an ... knowing the health risks. New research suggests that UV ... on the brains of some tanners (Go to goo.gl/hdwnz). ... I can’t say that I fully support this contention from ...
(Date:5/25/2013)... An experienced Chandler dentist has just launched ... Media Surge, LLC. , http://www.ChandlerDentalExcellence.com/Teeth-Whitening.php , ... on the treatment, can be performed in the office ... method will be chosen for the individual patient. , ... special peroxide-based whitening gel is used along with a ...
(Date:5/25/2013)... -- Many viruses and parasites that affect both dogs ... bacteria-borne illness than can result in liver or kidney ... to a veterinarian. These germs could be ... said Dr. Susan Nelson, a clinical associate professor at ... serious diseases can be fatal, even with treatment," she ...
(Date:5/25/2013)... Providing patients with their best weight loss is the ... professionals. But, aside from educating patients on how to ... diets also provide patients, who have gained weight because ... control over their lives by achieving their best weight loss. ... of weight gain derived from earlier abuse, Diet Doc's ...
(Date:5/25/2013)... By working diligently for months on ... of the 2012 Lamborghini Aventador into their well-built fitments ... in the list of vehicles lined by SizeItUp for ... set to thrill automobile lovers in the year 2013. ... looks, the 2012 Lamborghini Aventador comes with extraordinarily spacious ...
Breaking Medicine News(10 mins):Health News:Sun Damage – Are UV Rays Addictive? 2Health News:Chandler Dentist Launches Teeth Whitening Service Page on Website in Partnership with JD Media Surge, LLC 2Health News:Hidden Dangers Dog Dog Parks 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2
... Doxorubicin (DOX) is a red-colored anticancer drug that ... cardiac muscle deterioration (cardiomyopathy) and scar tissue accumulation ... due to inhibition by DOX of mitochondrial biogenesis, ... In a new study by Claude Piantadosi and ...
... a steroid slows progress of multiple myeloma, an incurable ... who have relapsed from previous treatment, researchers report in ... In the study conducted at 44 centers in the ... either a combination of lenalidomide (Revlimid(r)) and the steroid ...
... trials show "unprecedented" survival for patients with multiple myeloma, ... of bone marrow. The findings demonstrate that with Revlimid, ... significant improvement in patients where previous treatments had failed. ... study. Results of the study were published November 21 ...
... Smith brings free, national weight-loss initiative to Big Easy; Urges residents to ... ... Church, NEW ORLEANS, Nov. 21 Dr. ... to take control of their,health and give up the pounds to fight the ...
... Nov. 21 The following was issued,today by the ... talking, but he still isn,t saying,what he would do ... rest of,the Republican presidential candidates, his current rhetoric focuses ... an approach he,once said could not work. But, as ...
... Universal,Health Services, Inc. (NYSE: UHS ) announced today ... dividend of $0.08 per share on December 17,2007 to ... Universal Health Services, Inc. is one of the nation,s ... and,ambulatory centers nationwide and in Puerto Rico., Certain ...
Cached Medicine News:Health News:Drug combination effective against multiple myeloma, researchers show 2Health News:Drug combination effective against multiple myeloma, researchers show 3Health News:Oral drug sets a new survival standard for bone marrow cancer 2Health News:Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic 2Health News:Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic 3Health News:Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic 4Health News:DNC: Romney's Health Care Confusion Continues 2Health News:DNC: Romney's Health Care Confusion Continues 3
(Date:5/23/2013)... SAINT PAUL, Minn. , May 23, 2013 /PRNewswire/ ... Angeion Corporation), a global medical technology company, today scheduled ... the second quarter of fiscal year 2013, ended April ... ET on Thursday, May 30, 2013. The Company will ... year 2013 after the markets close on Thursday, May ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
... A Commonwealth Fund case study notes that ... aligned "to launch innovations and organize services in ways that make ... study -- along other profiles looking at medical systems that have ... high performing health care system -- has been in the works ...
... Conatus Pharmaceuticals Inc. announced today the initiation of a ... for the treatment of liver disease associated with Hepatitis C ... treatment with approved standard of care treatments is not currently ... patients who failed standard of care treatment are expected to ...
Cached Medicine Technology:Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 2Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 3Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... optical performance of the OMEGA 180, the ... better views of the fundus. A new ... Xenon Halogen Technology bulb produce less reflexes ... images of the fundus that are up ...
... The New 2.2 Fr Sur-Catch NT stone retrieval ... new level. Its unique paired wire design ... adjusts to the needs of each patient and ... designed specifically for use with the DURTM-8 Elite ...
Medicine Products: